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ABSTRACT: We have developed a panel of synthetic glycans
as receptor mimics for the speciﬁc capture of inﬂuenza viruses.
The glycans were printed onto commercial glass slides using a
free amine at the end of a spacer to generate a small focused
microarray. The microarray was evaluated for its ability to
capture three diﬀerent strains of inﬂuenza A virus, two H1N1,
A/Brisbane/59/2007 and A/Solomon Islands/3/2006 and one
H3N2, A/Aichi/2/1968. We observed an excellent detection
ability with some compounds exhibiting clinically relevant (101
plaque forming units) limit of detection. We also tested the
drug susceptibility of current antivirals, Zanamivir and
Ostelamivir using this microarray and could determine antiviral resistance for these strains.
Inﬂuenza virus is a respiratory pathogen that causes over 30000 deaths and 200 000 hospitalizations in the United States
annually.1 Pandemics, like the recent 2009 H1N1 “swine ﬂu”
can cause a signiﬁcant number of infections and death in
addition to disruption of economic activity.2,3 Inexpensive,
point of care diagnosis capable of detecting the virus rapidly
would be very useful to mitigate the eﬀects of the virus and
possibly arrest its spread. Additionally, early detection is
important because the antivirals lose their eﬃcacy if
administered 24−48 h after onset of infection in people with
weak or compromised immune systems.4,5 Measuring drug
susceptibility would provide primary care physicians with an
added diagnostic tool in support of their clinical decisions.
Monitoring drug susceptibility is especially important since
reports of inhibitors such as M2 ion channel protein, e.g.,
Amantadine and Neuraminidase (NA) inhibitors, e.g.,
Oseltamivir, resistance has been reported, the former exhibiting
widespread resistance.6−8 Antiviral resistance for the current
FDA approved drugs, Zanamivir and Oseltamivir and the
investigational drugs, Premavir and Laninamivir, is not easy to
perform and most certainly not applicable for point of care
diagnosis at this time. Traditional cell culture assays to test drug
susceptibility take a long time and therefore, these assays are
typically performed in a resourceful laboratory setting using
molecular markers that are known to cause NA inhibitor
resistance.9 Here, we report the synthesis and ability of sialic
acid analogues to capture inﬂuenza virus using three diﬀerent
strains. We have also developed an assay to monitor NA
inhibitor susceptibility of the virus toward the two major FDA
approved NA inhibitors, Zanamivir and Oseltamivir.
Inﬂuenza virus has two major surface glycoproteins,
Hemagglutinin (HA) and Neuraminidase (NA) that are
known to bind to N-acetyl neuraminic acids (sialic acids)
present on glycoproteins and glycolipids of the host cells.10 HA
is involved in the initial attachment of the virus to the host cells,
whereas NA is the enzyme that cleaves the residual sialic acid
from the remaining cells to facilitate release of the viral
progeny. These two inﬂuenza glycoproteins are excellent
targets for capturing inﬂuenza virus for use in diagnosis,
particularly because there are approximately 300 copies of HA
and 50 copies of NA on a single viral particle, respectively.11−13
Although several studies, including our own, have focused on
developing sialic acid based microarrays to capture HA to study
transmissibility of the virus,14−18 we focused on developing
molecules that capture NA in this report. This approach allows
us to monitor drug susceptibility since Zanamivir and
Oseltamivir are NA inhibitors.
■ EXPERIMENTAL SECTION
A. Chemical Synthesis and Characterization. The
synthesis and characterization of the compounds used in this
article are given in the Supporting Information.
B. Biological Assays. B.1. Immobilization of Glycans.
Synthetic glycans were covalently immobilized onto Nexterion
NHS slides using a DIGILAB OmniGrid Micro printer in 300
mM phosphate buﬀer with 0.005% Tween-20 at pH 8.5. Each
glycan was printed 20 times in quintuplicate at 200 μM
concentration. Following printing, the glycans were allowed to
react for 30 min at 60% humidity. After overnight desiccation,
the slides were blocked for 60 min with 50 mM ethanolamine
in 50 mM boric acid buﬀer (pH 9.5), washed 3 times with
deionized (DI) water, dried and stored at −20 °C.
B.2. Limit of Detection Assay. To determine the limit of
detection, a serial 10-fold dilution was performed for A/
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Brisbane/59/2007, A/Solomon Islands/3/2006 and A/Aichi/
2/1968 strains. The concentration of A/Brisbane/59/2007 was
tested from 2.4 × 106−2.4 × 101 plaque forming units (PFU),
A/Solomon Islands/3/2006 from 9.0 × 106−9.0 × 101 PFU
and A/Aichi/2/1968 from 1.5 × 106−1.5 × 101 PFU. Each
concentration of virus was applied to the microarray for 60 min
in a buﬀer consisting of PBS, 2% BSA and 0.05% Tween-20.
Postvirus incubation and wash (three times with PBS and
0.05% Tween-20 and two times with PBS), antibodies speciﬁc
to each virus were diluted and added to the microarray for 60
min. For A/Brisbane/59/2007, ferret hyperimmune sera to
inﬂuenza A/Brisbane/59/2007 (H1N1), NR-19260 was diluted
5000-fold, for A/Solomon Islands/3/2006 ferret hyperimmune
sera to inﬂuenza A/Solomon Islands/3/2006 (H1N1), NR-
19262 was diluted 1000-fold and for A/Aichi/2/1968
polyclonal anti-inﬂuenza virus A/Aichi/2/1968 (H3N2)
antiserum chicken, NR-3125 was diluted 5000-fold. Slides
were washed as described above and incubated for 60 min with
the appropriate ﬂuorescently tagged secondary antibodies. For
A/Brisbane/59/2007, antiferret IgG, IgA, IgM (H+L) rhod-
amine antibody was diluted 10 000-fold, for A/Solomon
Islands/3/2006 antiferret IgG, IgA, IgM (H+L), rhodamine
antibody was diluted 5000-fold and for A/Aichi/2/1968, Alexa
Fluor 633 goat antichicken IgG (H+L) was diluted 20 000-fold.
The slides were washed as described above, followed by a DI
water rinse. The slides were dried and scanned using the
GenePix4000B scanner. A/Brisbane/59/2007 and A/Solomon
Islands/3/2006 were scanned at 532 nm and A/Aichi/2/1968
at 635 nm. All experiments were performed in triplicate.
B.3. Drug Susceptibility Assay. To determine drug
susceptibility for A/Brisbane/59/2007, A/Solomon Islands/3/
2006 and A/Aichi/2/1968, each virus strain, 105 PFU, was
premixed with 10 ng of antiviral Zanamivir or Oseltamivir, for
30 min at rt. The premixed sample was subsequently added to
the microarray and allowed to incubate for 60 min.
Fluorescence intensity was measured as previously described
in the limit of detection methods. All experiments were
performed in triplicate.
■ RESULTS AND DISCUSSION
The structures of the eight molecules used to develop the
focused microarray are shown in Figure 1. There are several
salient features of the designer molecules. First, all eight
molecules are derived from the natural receptor, namely sialic
acid. Second, the molecules have a free amine at the end of a
spacer, which is necessary for facile attachment to an activated
carboxyl acid group on any surface. Third, the molecules also
have an amine or a guanidine group at the four position;
introduction of a polar group at the four position has been
demonstrated to be highly speciﬁc to inﬂuenza virus as X-ray
structures have shown that the polar group ﬁts very well into a
binding pocket of inﬂuenza virus NA, but does not ﬁt well into
human or bacterial NA.19 Fourth, we designed two types of
molecules; SC1−4 are sialic acid analogues that have spacers
Figure 1. Structures of the tailored glycans. The blue ellipse represents the two glycan headgroups, and I and II represent mono and bivalent
derivatives. The natural receptor, N-acetyl neuraminic acid (sialic acid), and the FDA approved antivirals, Zanamivir and Oseltamivir, are also
depicted.
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attached to the 2 position via a thiol linkage, in contrast, SC5−
SC8 are analogues derived from Zanamivir and attached to the
spacer at the 7 position.20−22 Finally, since we recently
demonstrated that molecules similar to SC1−4 and bivalent
molecules thereof, inhibited two H1N1 and H3N2 strains at
low nanomolar concentrations, we designed monovalent and
bivalent derivatives.23 The bivalent derivatives were synthesized
for two reasons. First, the bivalent scaﬀold provides additional
distance from the microarray surface for the NAs of the virus to
bind. Second, NA exists as a tetramer with four binding sites,
the distances between the two glycan headgroups are spaced
such that a single molecule could ﬁt into to two binding sites
from a single NA tetramer or alternatively, ﬁt into the pockets
of two adjacent NA tetramers on a single virion.23 When these
mono and bivalent molecules are tethered to a surface, the
overall binding aﬃnity of multiple glycans with inﬂuenza viruses
is expected to increase exponentially, leading to a higher
capturing eﬃciency.
The syntheses of the molecules are shown in Schemes 1 and
2. For SC1−4, the thioacetate group of the known azido
compound 124 was reacted with a suitable six carbon spacer,
which had a chloride at the terminus to yield 2 in appreciable
amounts. The azide was reduced under mild conditions using
triphenylphosphine and the amine group was either protected
by a tert-butoxy group or a suitably protected guanidine group
followed by replacement of the chloride by an azide using
sodium azide to yield 3a and 3b in decent yields. Zempleń
deprotection to remove the acetates and methyl ester was
followed by acidic removal of the tert-butoxy groups and
subsequent reduction of the azide using standard hydro-
genation conditions yielded the monovalent compounds SC1
and SC2, which had an amine and a guanidine group at the four
position of the sialic acid, respectively. Copper(I) catalyzed 1,3
dipolar addition of 3a,b with a dimeric scaﬀold, 4, bearing two
alkyne groups resulted in the fully protected bivalent
compounds, 5a,b, in good yields. The protecting groups were
removed using the same conditions as described for the
monovalent derivatives to yield the bivalent compounds, SC3−
4. For the Zanamivir analogues, SC5−8, we attached the spacer
to the seven hydroxyl group as modiﬁcations at this position are
well tolerated by NA; indeed, this approach has been used to
attach a biotin to Zanamivir.20 To this end, we elaborated the
known azido compound 620−22 by reducing the azide and
protecting the free amine group using a tert-butoxy group to
yield 7 in high yields. This was followed by base induced
deprotection of the acetate groups and acetonide protection of
Scheme 1. Reagents and Conditionsa
a(a) 6-Chlorohexyl 4-methylbenzenesulfonate, DEA, DMF, rt, 4 h. 80% (b) i. PPh3, THF/H2O (1:1), 40 °C, 12 h. ii. (t-Boc)2O, TEA, THF, 60%. iii.
NaN3, DMF, 60 °C. 90%. (c) i. PPh3, THF/H2O (1:1), 40 °C, 12 h. ii. 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, HgCl2, 85%.
iii. NaN3, DMF, 60 °C. 93%. (d) Na-L-ascorbate, CuSO4, THF/H2O. 12 h, 60% for 5a; 65 for 5b. (e) i. NaOMe, MeOH. ii. DCM/TFA. iii. NaOH,
MeOH, 80% yield for SC3, 70% yield for SC4. (f) H2, Lindlar catalyst, EtOH/H2O, 4 h, 75% yield for SC1, 70% yield for SC2.
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the 8,9 hydroxyl groups, leaving the hydroxyl group at the seven
position open for conjugation to the spacer. The terminal
amine of a six carbon spacer bearing an azide group at the
opposite end was conjugated to 8 in a two-step procedure using
p-nitrochloroformate as the coupler to yield the carbamate 9.
The acetonide group was removed under mild acidic conditions
to produce 10a. The guanidine derivative, 10b, was synthesized
from 10a, the tert butoxy group was removed and a suitably
protected guanidine group was attached to the free amine to
yield 10b in signiﬁcant amounts. This strategy of installing the
guanidine group at this later stage was more successful in our
hands as opposed to introducing the guanidine group early in
the synthesis, the latter strategy gave us undesirable products
and variable results. Global deprotection of 10a,b was
performed as described for SC1,2 to yield SC5,6 in good
yields. The bivalent derivatives SC7,8 were synthesized from
10a,b in a manner similar to the synthesis of SC3,4 by coupling
to the scaﬀold 4, followed by global deprotection. The ﬁnal
compounds were puriﬁed using size exclusion chromatography
using Biogel P2 and the appropriate fractions containing the
compounds were freeze-dried to produce colorless foamy solid
material.
The synthetic glycans were printed onto commercial glass
slides bearing activated carboxyl groups for conjugation to the
free amines of SC1−8 to produce a focused microarray.
Printing was performed at various concentrations; we used a
concentration of 200 μM for all assays in this report as it gave
us excellent signal-to-noise ratio. Amine terminated PEG was
printed as a negative control. Amine terminated biotin was
included as a positive control. The microarray was exposed to
three diﬀerent strains of inﬂuenza virus, two H1N1, A/
Brisbane/59/2007 and A/Solomon Islands/3/2006 and a
H3N2, A/Aichi/2/1968. The strains were incubated at rt for
60 min, followed by incubation of the appropriate primary and
ﬂuorescently labeled secondary antibody. The slides were
washed at every stage extensively, and the slides were scanned
Scheme 2. Reagents and Conditionsa
a(a) H2, Lindlar catalyst, EtOH, 4 h, quant. (b) Boc2O, TEA, THF, 12 h, 86%. (c) NaOMe, MeOH, 1 h, quant. (d) H
+ resin, acetone, 12 h, 88%. (e)
DMAP, pyridine, p-NO2C6H4OCOCl, 12 h, 80%. (f) 6-Azido-hex-1-amine, CH3CN, TEA, 3 h, 89%. (g) TFA, DCM. (h) 1,3-Bis(tert-
butoxycarbonyl)-2-methyl-2-thiopseudourea. HgCl2, TEA, DCM, 12 h, 84%. (i) Na-L-ascorbate, CuSO4, THF/H2O, 12 h. 78% for 11a; 80% for
11b. (j) NaOH, MeOH. 1 h. 70% for SC7; 79% for SC8. (k) H2, Lindlar catalyst, EtOH, 4 h. 76% for SC5; 72% for SC6.
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using a Genepix scanner at 532 or 635 nm. Reproduced in
Figure 2A is the ﬂuorescence image where the microarray was
exposed to 105 PFU of H1N1 Inﬂuenza virus A/Brisbane/59/
2007. The image clearly shows that the bivalent compounds,
SC3,4,7,8, captured the virus very well; however, most of the
monovalent compounds, SC1,2,5,6, bind weakly to this strain,
suggesting that the bivalent derivatives provide the required
distance from the surface for the virus to bind. We and others
have observed this phenomenon before, binding of glycans to
their respective analytes are highly dependent on glycan density
and presentation.14,25 Exposure to H3N2 strain A/Aichi/2/
1968 resulted in similar results (Figure 3C); however, all
compounds bound to H1N1 A/Solomon Islands/3/2006,
indicating that this virus strain is more accommodating in its
binding preferences. (Figure 3B). Nonspeciﬁc binding to the
control ligand, PEG, was negligible, which is a very important
aspect of biosensor development as viruses are notorious in
terms of nonspeciﬁc binding. Several other controls (with
buﬀer only, using other synthetic glycans) were performed and
all of these control experiments resulted in no binding. We
observed a diﬀerential response to the ligands for each viral
strain, for example, the A/Aichi/2/1968 strain exhibits similar
binding to all four bivalent compounds, the A/Brisbane/59/
2007 strain binds better to the bivalent compounds, SC4 and
SC8, with the guanidine group at the four position. With more
ligands and slight diﬀerences in the binding aﬃnities, this
diﬀerential pattern could potentially be used to develop a
“ﬁngerprint” pattern of recognition for each strain, including
emerging strains.26
Next, we determined the analytical limit of detection using
diﬀerent concentrations of the diﬀerent strains from 106 to 101
PFU. As shown in Figure 3A−C, the bivalent compounds bind
to the three diﬀerent strains at higher concentrations very well
with high relative ﬂuorescence intensities. At the lowest tested
concentration of 101 PFU, the bivalent compounds SC3 and
SC7 bind well to the H1N1 A/Brisbane/59/2007 and the A/
Solomon Islands/3/2006 strains; however, SC3 and SC1 bind
to the H3N2 A/Aichi/2/1968 strain. Known diﬀerences in the
binding pockets of N1 and N2 could be a possible reason for
this diﬀerence in binding at lower concentrations in addition to
the number of NAs present on the surface of each strain.27 We
note that these ﬁrst generation ligands can capture extremely
low clinically relevant concentrations of viruses and further
optimization could lead to lower limits of detection. Finally, we
tested the microarray for susceptibility to FDA approved
antivirals, Zanamivir and Oseltamivir (Figure 4). Brieﬂy, known
concentrations of the three strains were premixed with either
one of the antivirals and exposed to the microarray. Washing to
remove unbound virus was followed by detection using the
appropriate primary and labeled secondary antibody. It was
gratifying to observe no binding to any of the compounds for
all three strains, which indicates that the antiviral blocks the NA
leading to loss of signal. There are two outliers, SC3 and SC7.
In the presence of antivirals, SC3 binds H3N2 A/Aichi/2/1968
strain and SC7 binds both H1N1 strains. A possible explanation
for these observations could be that the binding pocket of HA
for each particular strain could accommodate sialic acid with an
amine at the 4 position, which is similar to the structure of the
glycan head groups in SC3 and SC7.
■ CONCLUSIONS
We have synthesized tailored glycans, printed them onto glass
slides and demonstrated the ability of a focused microarray to
capture three inﬂuenza strains at diﬀerent concentrations. We
determined the limit of detection to be 101 PFU, which
indicates that the assay is clinically relevant. We also
demonstrated that the assay can be used to test drug
susceptibility of current FDA approved antivirals, Zanamivir
and Oseltamivir, by premixing the antivirals with the strains and
performing the assay. Thus, the assay reported in this article
can be performed rapidly within hours using minimal tools. In
contrast, current genotyping methods to determine antiviral
resistance is typically performed in a clinical laboratory using
molecular markers by trained personnel, specialized equipment
and days to accomplish. We are currently expanding our eﬀorts
to develop second generation ligands and include more strains
Figure 2. Inﬂuenza virus binding studies. (A) Fluorescence image of microarray containing eight glycans (SC1−SC8) after exposure to 105 PFU of
H1N1 Inﬂuenza A/Brisbane/59/2007, followed by ferret hyperimmune sera and antiferret rhodamine labeled secondary antibody for A/Brisbane/
59/2007 and scanned by Genepix scanner at 532 nm. (B) Fluorescence detection of H1N1 (A/Brisbane/59/2007) inﬂuenza A virus using synthetic
glycans. Glycans, PEG (negative control) and biotin (positive control) were printed at 200 μM. Virus concentration was 105 PFU. Fluorescence
intensity was measured by the Genepix scanner using ferret hyperimmune sera to inﬂuenza A/Brisbane/59/2007 (H1N1) and antiferret rhodamine
labeled antibody. A/Brisbane/59/2007 was scanned at 532 nm. The experiment was performed in triplicate.
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to demonstrate broad applicability. By further optimization of
ligand structure, testing diﬀerent conditions and biosensor
platforms, this assay has the potential to be translated to rapid
diagnostic tests.
Figure 3. Analytical sensitivity studies. Limit of detection for (A)
H1N1 Inﬂuenza A/Brisbane/59/2007, (B) H1N1 Inﬂuenza A/
Solomon Islands/3/2006 (C) H3N2 Inﬂuenza A/Aichi/2/1968.
Fluorescence intensity for A/Brisbane/59/2007 was measured as
previously described for Figure 2. Fluorescence intensity was measured
by the Genepix scanner using ferret hyperimmune sera to inﬂuenza A/
Solomon Islands/3/2006 (H1N1) and antiferret rhodamine labeled
antibody; polyclonal antiserum chicken to A/Aichi/2/1968 (H3N2)
and Alexa Fluor 633 labeled antichicken. A/Solomon Islands/3/2006
was scanned at 532 nm and A/Aichi/2/1968 at 635 nm. All
experiments were performed in triplicate.
Figure 4. Drug susceptibility studies. (A) H1N1 Inﬂuenza A/
Brisbane/59/2007. (B) H1N1 Inﬂuenza A/Solomon Islands/3/2006.
(C) H3N2 Inﬂuenza A/Aichi/2/1968. Ten nanograms of antivirals
Zanamivir or Oseltamivir were premixed with the strains at 105 PFU
for 30 min at rt and subsequently added to the microarray.
Fluorescence intensity was measured as previously described in
Figures 2 and 3. All experiments were performed in triplicate.
Analytical Chemistry Article
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